Ecofriendly chromatographic methods for determination of co-prescribed drugs, olanzapine and metformin, in rat plasma
Background: Olanzapine (OLZ) is one of most recommended drugs for the treatment of schizophrenia while metformin (MET) is the most commonly used hypoglycemic agent. Aim: Development and validation of two green, sensitive and accurate chromatographic methods for the simultaneous determination of OLZ along with the co-prescribed, MET. Materials & methods: TLC-densitometric method with a developing system consisting of methylene chloride:methanol:ethyl acetate:triethylamine (4:4:5:0.1, by volume) and a reversed-phase (RP)-HPLC method where the chromatographic separation was performed using ethanol:water mixture (50: 50, v/v) as a mobile phase. Results: TLC-densitometric method had linearity over concentration ranges of 160-4000 ng/band for OLZ and 150-4500 ng/band for MET, while RP-HPLC method was linear and validated over concentration range of 300-20000 ng/ml for OLZ and MET. Conclusion: Pharmacokinetic study was successfully performed and suggested the possibility of co-administration of MET with OLZ and their further formulation in one pharmaceutical preparation to enhance patient's compliance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Bioanalysis - 12(2020), 9 vom: 24. Mai, Seite 597-613 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emam, Aml A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 26.01.2021 Date Revised 26.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2020-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310237807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310237807 | ||
| 003 | DE-627 | ||
| 005 | 20231225135647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2020-0009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310237807 | ||
| 035 | |a (NLM)32441535 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emam, Aml A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ecofriendly chromatographic methods for determination of co-prescribed drugs, olanzapine and metformin, in rat plasma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2021 | ||
| 500 | |a Date Revised 26.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Olanzapine (OLZ) is one of most recommended drugs for the treatment of schizophrenia while metformin (MET) is the most commonly used hypoglycemic agent. Aim: Development and validation of two green, sensitive and accurate chromatographic methods for the simultaneous determination of OLZ along with the co-prescribed, MET. Materials & methods: TLC-densitometric method with a developing system consisting of methylene chloride:methanol:ethyl acetate:triethylamine (4:4:5:0.1, by volume) and a reversed-phase (RP)-HPLC method where the chromatographic separation was performed using ethanol:water mixture (50: 50, v/v) as a mobile phase. Results: TLC-densitometric method had linearity over concentration ranges of 160-4000 ng/band for OLZ and 150-4500 ng/band for MET, while RP-HPLC method was linear and validated over concentration range of 300-20000 ng/ml for OLZ and MET. Conclusion: Pharmacokinetic study was successfully performed and suggested the possibility of co-administration of MET with OLZ and their further formulation in one pharmaceutical preparation to enhance patient's compliance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a RP-HPLC | |
| 650 | 4 | |a TLC densitometry | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a olanzapine | |
| 650 | 4 | |a pharmacokinetic | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Olanzapine |2 NLM | |
| 650 | 7 | |a N7U69T4SZR |2 NLM | |
| 700 | 1 | |a Habib, Neven M |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoud, Hamada M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelwhab, Nada S |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrahman, Maha M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 12(2020), 9 vom: 24. Mai, Seite 597-613 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:9 |g day:24 |g month:05 |g pages:597-613 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2020-0009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 9 |b 24 |c 05 |h 597-613 | ||